Systemic Therapy Strategies for Treating Neuroendocrine Tumors

The doctors cover the use of next generation sequencing for newly diagnosed patients, highlighting that although results rarely changes upfront management, it can occasionally reveal actionable findings such as high tumor mutation burden and mismatch repair deficiency. In addition to NGS, care should prioritize imaging, pathology review, and multidisciplinary collaboration and planning. They then review several clinical trials, including the NETTER-2 and CLARNET FORTE trials to evaluate the role of peptide receptor radionuclide therapy (PRRT) and somatostatin analog (SSA) therapy while considering sequencing of multimodal treatments. The episode wraps up with ongoing and future clinical trials investigating other potential therapies for NETs.